epirubicin / Generic mfg. - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma (ASH 2025) - "Introduction The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) has been established as the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) in clinical practice...Pomalidomide, a third-generation immunomodulatory agent, exhibits more potent immunomodulatory effects compared to lenalidomide...Pomalidomide-rituximab was combined with CHOP-like regimens (n = 10), bendamustine (n = 1), brentuximab vedotin (n = 1), or BTK inhibitors (n = 2)...Grade 3-4 non-hematological AEs occurred in four patients, including one with hyponatremia and three with infections. Conclusion This real-world analysis demonstrated that the pomalidomide-rituximab-based combination therapy had promising efficacy, with a high ORR of 92.9%, in treatment-naïve DLBCL patients with extranodal disease, and exhibited acceptable hematological toxicity."

Clinical • Combination therapy • Real-world • Real-world effectiveness • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Heart Failure • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • CD5 • TP53

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results (ASH 2025) - P2 | "This study aims toevaluate the efficacy and safety of daratumumab-carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation (ASCT) inthis population (NCT06140966). In this multicenter phase 2 trial , transplant-eligible NDMM patients (aged 18-70 years; ECOG ≤2before induction therapy) with UHiR (defined as "double-hit" MM (≥2 high-risk cytogenetic abnormalities[HRCAs]: t(4; 14), t(14; 16), t(14; 20), 1q+, del(17p), TP53 mutation), extramedullary disease (EMD), orprimary plasma cell leukemia (pPCL)) received 1 cycle of pretrial induction therapy with regimens such asVRD, VCD, or KRD, followed by induction with 2-4 cycles of Dara-KRd-PACE (Daratumumab 16 mg/kg days1,8; Carfilzomib 20/27 mg/m² days 1,2,8,9; Lenalidomide 25 mg days 1-7; Dexamethasone 40 mg days1,8,15,22; Cisplatin 10 mg/m² days 1-4; Epirubicin 10 mg/m² days 1-4; Cyclophosphamide 400 mg/m² days1-4; Etoposide 40 mg/m² days..."

Clinical • Infectious Disease • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia • Thrombosis • Transplantation • CD34 • TP53

Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization (ASH 2025) - "Following China's approval of Pola-R-CHP (polatuzumab vedotin combined withrituximab, cyclophosphamide, doxorubicin, and prednisone) for first-line DLBCL treatment in April 2023,this multicenter retrospective study aimed to evaluate its efficacy as initial therapy for CD5-positiveDLBCL.We conducted a retrospective study involving treatment-naïve CD5-positive DLBCL patients whoreceived Pola-R-CHP as first-line therapy between April 2023 and November 2024 at six institutions.Polatuzumab vedotin was administered 1.8 mg/KG, rituximab 375 mg/m2, cyclophosphamide 750mg/m2, doxorubicin 50 mg/m2 or epirubicin 70 mg/m2, all intravenously on Day 1. CD5-positive DLBCL patients demonstrated rapid responses to Pola-R-CHP, with the regimen exhibitinga favorable safety profile. Patients failing to achieve CR at interim evaluation are unlikely to attain CRby treatment completion, suggesting a potential need for earlier therapeutic modification."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • B2M • CD20 • CD5

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China (ASH 2025) - "About 65% of the patients had at least one comorbidity, withthe most common being hypertension (38%), renal disorders (35%), cardiovascular diseases (31%),diabetes (18%), and liver disorders (17%).Ixazomib-based regimens consisted of combinations such as Ixazomib plus IMiD with or without otheragents (e.g., IR[Ixazomib, lenalidomide], ITd[Ixazomib, thalidomide, dexamethasone], IPd[Ixazomib,pomalidomide, dexamethasone], IRAd[Ixazomib, lenalidomide, aclarubicin, dexamethasone],IRCd[Ixazomib, lenalidomide, cyclophosphamid, dexamethasone]) and Ixazomib plus dexamethasonewith or without additional agents (e.g., ICd[Ixazomib, cyclophosphamid, dexamethasone], IACd[Ixazomib,aclarubicin, cyclophosphamid, dexamethasone], Id + epirubicin, ICd + epirubicin , Id + denosumab,IMd[Ixazomib, melphalan, dexamethasone]). Survival outcomes remain under ongoing follow-up. Thesefindings suggest that ixazomib-based therapy may serve as a viable first-line treatment option, even forpatients..."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Diabetes • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease

DP13 Keep calm and shoulder on: a lesion that can't be shrugged off. (PubMed, Br J Dermatol) - "The second cycle of adjuvant chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide) caused right-upper-limb phlebitis and lymphangitis with permanent damage to local vasculature...She was on hydroxychloroquine for long-standing rheumatoid arthritis, having previously received methotrexate and sulfasalazine...Some cases described in the literature as APL in irradiated areas are possibly the lymphatic subtype of an AVL. As there was no latency between irradiation and onset, our case is more likely APL, rather than AVL outside the field of irradiation."

Journal • Angiosarcoma • Breast Cancer • Epstein-Barr Virus Infections • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Sarcoma • Solid Tumor • CD31 • CD34 • MYC • PECAM1

DARLING-02: Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） (clinicaltrials.gov) - P2 | N=144 | Recruiting | Sponsor: Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 ➔ Dec 2028 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Head-to-Head • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy of anti-emetic therapy in highly emetogenic chemotherapy-induced nausea and vomiting in breast cancer patients: A prospective observational study from a tertiary care centre (ESMO Asia 2025) - "This study evaluates whether low-cost olanzapine offers comparable QOL preservation in a South Indian cohort. This prospective observational study (June 2022–December 2023) at a single South Indian center included 113 breast cancer patients receiving highly emetogenic chemotherapy (Adriamycin/Epirubicin + Cyclophosphamide). Olanzapine maintained QOL and controlled nausea comparably to NK-1 RAs in breast cancer patients on HEC, though NK-1 RAs achieved higher CR rates for CINV. Given its lower cost and steroid-sparing potential, olanzapine is a viable alternative in resource-limited settings for preserving QOL while providing reasonable emesis control."

CINV • Clinical • Observational data • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

Paradox of perioperative chemotherapies FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) vs EOX (Epirubicin, oxaliplatin and capecitabine) in non-metastatic gastric carcinoma survival– A retrospective analysis (ESMO Asia 2025) - "FLOT regimen showed nonsignificant favourable survival outcomes and tumour downstaging. The OS/PFS outcomes are less compared to randomised studies. Need prospective study comparing EOX vs FLOT as well as molecular exploratory research."

Metastases • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Pegylated liposomal doxorubicin-based neoadjuvant immunochemotherapy for early-stage TNBC: A Taiwanese multicenter experience (ESMO Asia 2025) - "While this study predominantly used conventional anthracycline (doxorubicin or epirubicin), pegylated-liposomal doxorubicin (PLD) represents an alternative anthracycline formulation that may be used in pembrolizumab-based regimens. Whether PLD offers clinical benefit remains unclear, and real-world evidence is lacking to guide clinical practice. A total of 52 patients with stage I-III triple-negative breast cancer received neoadjuvant sequential taxane-platinum (4 cycles) followed by PLD-cyclophosphamide (4 cycles), with concurrent pembrolizumab (100mg or 200mg, Q3W), at five medical centers in Taiwan (2020-2024)... This retrospective study reveals the real-world evidence of sequential PLD with pembrolizumab therapy in early-stage TNBC patients. Notably, pCR and rCR rates in this multicenter cohort were lower than those reported in the KEYNOTE-522 trial, but trends favored the dose of 200 mg pembrolizumab (Q3W), suggesting a potential dose-response relationship. Ki-67..."

Clinical • Oncology • Triple Negative Breast Cancer

Sacituzumab Govitecan Combined with Anti-angiogenic Therapy and Radiotherapy in a BRCA1-Mutated Triple-Negative Breast Cancer Patient with Multiple Recurrences: A Case Report (SABCS 2025) - P2 | "She underwent left modified radical mastectomy, followed by 8 cycles of adjuvant chemotherapy (epirubicin + cyclophosphamide, followed by paclitaxel)...In December 2020, right chest wall recurrence was found, treated with local extended resection in January 2021, and followed by one-year oral capecitabine.In June 2023, she developed lung metastases (germline BRCA1 mutation),then enrolled in an IIT trial (NCT05085626) where she received Fluzoparib + Chidamide, achieving partial response (PR) with a progression-free survival (PFS) of 14 months...She declined brain surgery and received Bevacizumab + Trastuzumab Deruxtecan...Treatment with SG in combination with Anlotinib was initiated, accompanied by concurrent WBRT during the first cycle... This case report highlights the potential efficacy of SG in combination with anti-angiogenic therapy and radiotherapy in treating BRCA1-mutated TNBC patients with multiple recurrences and brain metastases. However, further studies..."

Case report • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • HRD • PGR

The Pharmacological Atlas of Meningiomas (SNO 2025) - "The top five drugs with the lowest IC50 values were romidepsin, dactinomycin, carfilzomib, plicamycin, and omacetaxine, with median values of 10, 31, 145, 303, and 400 nM, respectively. Considering the ratio of peak serum concentration (Cmax) to IC50 as a potential predictor of treatment efficacy (>1), the HDAC inhibitors belinostat (74.5), romidepsin (69.7), along with the proteasome inhibitor carfilzomib (34.6), and the anthracyclines epirubicin (2.6), and doxorubicin (1.8), and the PI3K inhibitor idelalisib (1.6) are the most promising drug candidates for further evaluation. This study offers the first comprehensive insight into the pharmacological landscape of meningiomas, providing a crucial foundation for future clinical trials aimed at developing systemic treatments for aggressive meningiomas."

Brain Cancer • Meningioma • Solid Tumor

Global insights into the management of BCG-unresponsive non-muscle invasive bladder cancer: a narrative review of provider surveys. (PubMed, Transl Androl Urol) - "Preferences for intravesical chemotherapy agents differed by region: gemcitabine (Gem) was commonly used in the US and Arab countries; epirubicin and doxorubicin were favored in China; mitomycin C (MMC) was preferred in Europe. While most urologists were familiar with gemcitabine/docetaxel (Gem/Doce), its actual use in clinical practice remained limited...Notably, at the time of the surveys, newly Food and Drug Administration (FDA)-approved therapies like nadofaragene and pembrolizumab were rarely used. Global practice patterns for BCG-unresponsive disease vary widely across regions, highlighting the need for a more unified, consensus-driven approach to the use of evolving bladder-sparing therapies and clinical guidelines."

Journal • Review • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urology

Retrospective analysis of the clinical efficacy of neoadjuvant chemotherapy albumin paclitaxel combined with carboplatin in the treatment of triple-negative breast cancer. (PubMed, Sci Rep) - "According to the differences in NAC regimens, they were categorized into TCb group (n=50), docetaxel + doxorubicin + cyclophosphamide (TAC group, n=60), and epirubicin combined with cyclophosphamide followed by docetaxel (EC-T group, n=40). TNBC patients with high levels of NPAR, severe neutropenia, high Ki-67 expression, and lymph node stage I are more likely to achieve pCR. In addition, NPAR, Ki-67 expression and severe neutropenia were all good predictors of pCR, the better performance in predicting pCR after combining multiple metrics."

Journal • Retrospective data • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • MUC16

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. (PubMed, J Clin Oncol) - "Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged."

Journal • P3 data • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) (CTOS 2025) - No abstract available

Clinical • Metastases • P1 data • Oncology • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Primary testicular diffuse large B-cell lymphoma with gonadal vein tumor thrombus: A case report and review of the literature. (PubMed, World J Clin Oncol) - "This case demonstrates the diagnostic complexities of PTL with gonadal vein tumor thrombus, underscoring the importance of considering lymphoma in elderly patients with testicular masses and venous involvement. A multi-disciplinary team including urologists, hematologists, and radiation oncologists is needed to ensure appropriate therapy."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Testicular Cancer • Thrombosis • BCL2 • CD20 • IRF4

Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines. (PubMed, EBioMedicine) - "Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ADORA2A • CTSB

Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression. (PubMed, Front Biosci (Landmark Ed)) - "Epirubicin exerts anti-myeloma effects by downregulating CDC20 and inducing cell-cycle arrest in MM, highlighting CDC20 as a potential biomarker for identifying MM patients likely to benefit from epirubicin."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CCNB1 • CDC20 • FAM72A • KIF20A • LMNB1

Linperlisib Combined With Chidamide in Patients With PTCL (clinicaltrials.gov) - P1/2 | N=134 | Recruiting | Sponsor: Yanyan Liu | N=100 ➔ 134 | Trial completion date: May 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Metabolomic changes associated with treatment response of neoadjuvant chemotherapy with TEC regimen in HER2-negative breast cancer. (PubMed, Front Pharmacol) - "This study aimed to characterize time-dependent metabolic alterations and identify metabolites associated with treatment response in HER2-negative breast cancer patients undergoing neoadjuvant chemotherapy (NAC) with the TEC regimen (docetaxel, epirubicin, and cyclophosphamide)...Following six cycles, elevated epinephrine levels were positively associated with therapeutic efficacy, while increased cysteine levels were linked to unfavorable outcomes...Combined analysis of ursodeoxycholic acid and cysteine improved the predictive performance for treatment response. These findings reveal dynamic metabolic reprogramming during NAC and suggest that ursodeoxycholic acid and cysteine may serve as potential predictive biomarkers of therapeutic efficacy in HER2-negative breast cancer patients treated with the TEC regimen."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

OTT15-04: Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (clinicaltrials.gov) - P4 | N=2 | Terminated | Sponsor: Ottawa Hospital Research Institute | Completed ➔ Terminated; The study did not meet the pilot feasibility endpoints and was formally closed to accrual prematurely on February 8, 2017.

Trial termination • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Neoadjuvant Dalpiciclib Plus Letrozole Versus Standard Chemotherapy in High-Risk HR+/HER2- Negative Breast Cancer (DARLING-02): A Randomized Phase II Trial (SABCS 2025) - P2 | "The control arm received epirubicin 100 mg/m² plus cyclophosphamide 500 mg/m² intravenously on day 1 every 3 weeks for 4 cycles, followed by docetaxel 100 mg/m² intravenously on day 1 every 3 weeks for 4 cycles. These findings support dalpiciclib plus letrozole as a promising neoadjuvant option for patients with high-risk HR+/HER2- early breast cancer and warrant confirmation in phase III trials."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Trofuse-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hormone receptor-low-positive (HR-low+)/ human epidermal growth factor receptor 2-negative (HER2−) breast cancer (SABCS 2025) - P3 | "Sacituzumab tirumotecan or sac-TMT (also known as MK-2870/SKB264), a novel antibody-drug conjugate composed of an anti-TROP2 antibody coupled to a cytotoxic belotecan derivative via a novel linker, has demonstrated significant PFS and OS benefits vs chemo in patients with metastatic TNBC...Participants are randomized 1:1 to neoadjuvant pembro plus sac-TMT followed by pembro plus paclitaxel plus carboplatin (arm 1) vs pembro plus paclitaxel plus carboplatin followed by pembro plus doxorubicin or epirubicin plus cyclophosphamide (arm 2; Table)...Secondary endpoints include OS, pCR-no DCIS (ypT0 ypN0), distant progression- or distant recurrence-free survival, patient-reported outcomes, and safety. Enrollment is ongoing."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • TACSTD2

Sequencing Matters: Impact of EC-first versus Carboplatin-first Ordering on pCR in Triple-Negative Breast Cancer Real-World-Data (SABCS 2025) - "BackgroundKeynote-522 administers four cycles of Carboplatin + Paclitaxel (Carbo/P) together with pembrolizumab (Pembro), followed by Doxorubicin/Epirubicin + Cyclophosphamide (EC). Of note, there were considerably more stage III patients than in the trial population—potentially harder to sterilise—which may account for the lower pCR rates seen. These real-world findings support prospective evaluation of an EC-first sequence and emphasise the importance of maintaining dose intensity in everyday practice."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2